The firm, launched last September, said in an SEC document that it is targeting $5 million in the financing round.
Researchers involved with the WGS500 study reported on findings from more than 150 clinical cases assessed by whole-genome sequencing.
The partners will sequence genes known to affect drug metabolism and response to create electronic medical record alerts and find clinically relevant gene variants.
Quest has been offering the test since April 13 through its Quest Diagnostics Nichols Institute in San Juan Capistrano, California.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.
Adam Rutherford discusses genetic genealogy at the Guardian.
Portions of the US 21st Century Cures Act are raising some safety concerns.
David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.